Duration: 90 Minutes


$390 

Purchase Options: *

Learn More


Lab Developed Tests are IVDs under the US FDA definition, including when the manufacturer of the IVD is a laboratory. IVDs are intended for use in the collection, preparation, and examination of specimens taken from the human body, and can be used to measure or detect substances or analytes in the body to provide information about a patient's health, including to diagnose, monitor, or determine treatment for diseases and conditions.

The LDT final rule amends the FDA's regulations to make explicit that IVDs are devices under the FD&C Act, including when the manufacturer of the IVD is a laboratory. This amendment is not specific to certain types of LDTs, but rather relates to all IVDs manufactured by laboratories. In addition, the preamble to the LDT final rule describes a tailored phaseout policy under which the FDA will provide greater oversight of IVDs offered as LDTs through a phaseout of its general enforcement discretion approach for LDTs over the course of four years. The phaseout policy includes targeted enforcement discretion policies for specific categories of IVDs, including policies for currently marketed IVDs offered as LDTs and LDTs for unmet needs under certain circumstances.  As described in the preamble to the final rule, the FDA intends to exercise enforcement discretion with respect to premarket review and most Quality System (QS) requirements for currently marketed IVDs offered as LDTs that were first marketed before the LDT final rule issued. Additionally, as described in the preamble to the final rule, the FDA intends to exercise enforcement discretion with respect to premarket review and most QS requirements for LDTs manufactured and performed by a laboratory integrated within a health care system to meet an unmet need of patients receiving care within the same health care system. However, FDA expects compliance with other device requirements for IVDs falling within these policies.


Why You Should Attend:


The FDA is phasing out the general enforcement discretion approach for LDTs so that IVDs manufactured by laboratories will generally fall under the same enforcement approach as other IVDs. Compliance with device requirements under the FD&C Act will help assure IVDs offered as LDTs are appropriately safe and effective and put patients in a better position to have confidence in IVDs regardless of where they are manufactured. Device requirements include, among others:

  • Adverse Event Reporting
  • Establishment Registration
  • Device Listing
  • Labeling Requirements
  • Investigational Use requirements
  • Quality System Requirements
  • Premarket Review


Areas Covered in the Session :


  • The LDT final rule 
  • LDTs are IVDs
  • The FDA's various enforcement options with LDTs
  • Reductioin in uncertainty re FDA and LDTs
  • The meaning of the FDA's "enforcement discretion
  • Key changes under the Final Rule
  • Modified and unmodified LDTs


Who Should Attend:


  • Senior management in Devices, Combination Products
  • Quality Assurance Departments
  • Regulatory Affairs Departments
  • Research and Development Departments
  • Manufacturing Departments
  • Engineering Departments
  • Operations Departments
  • Production Departments
  • Medical Device product development teams
  • Consultants



Course Director: JOHN E. LINCOLN

John E. Lincoln, is Principal of J. E. Lincoln and Associates LLC, a consulting company with over 36 years experience in U.S. FDA-regulated industries, 22 of which are as an independent consultant. John has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan. He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process / product / equipment QMS and software validations, ISO 14971 product risk management files / reports, Design Control / Design History Files, Technical Files, CAPA systems and analysis.

He’s held positions in Manufacturing Engineering, QA, QAE, Regulatory Affairs, to the level of Director and VP (R&D). In addition, John has prior experience in military, government, electronics, and aerospace. He has published numerous articles in peer reviewed journals, conducted workshops and webinars worldwide on CAPA, 510(k)s, risk analysis / management, FDA / GMP audits, validation, root cause analysis, and others. He writes a recurring column for the Journal of Validation Technology. John is a graduate of UCLA.






















Eventura World's refund policy applies to each product and service as detailed on the respective offering pages. If no specific refund policy is mentioned for an offering, the following general policy applies:

Cancellation by Registrant:
  • Registrants may cancel their registration for any reason up to 2 business days prior to the event. A refund will be issued minus a $45 administrative fee.
  • If a cancellation occurs after materials such as documents, handouts, checklists, slide deck, or recordings have been sent by Eventura, only 40% of the registration fee will be refunded.
  • If the registrant fails to cancel within the stipulated time or does not attend the event, no refund will be issued. Options available to the registrant in such cases include:
    1. Access to a one-time recording of the event.
    2. A redeemable voucher.
Substitutions:
Substitutions of attendees may be made at any time by notifying Eventura via email.

Cancellation by Eventura:
  • Eventura reserves the right to cancel or reschedule an event due to insufficient registrations or unforeseen circumstances. Registrants will be notified via email prior to the event's start time unless prevented by situation beyond control.
  • If an event is rescheduled, registrants will be promptly informed of the new date and their registration will be automatically transferred.
  • If the new date is not suitable, registrants may choose from the following options:
    1. Access to a one-time recording of the webinar after the live session.
    2. A redeemable voucher valid for 12 months, applicable towards any future live event or past recording.
  • A full refund will be issued if no new date is provided within 90 days from the originally scheduled event date.
Event Cancellation:
If an event is permanently cancelled, registrants may opt for:
  • A recording of the webinar, if available.
  • A redeemable voucher.
  • A full refund.
Changes to Event Details:
Eventura reserves the right to modify some topics, materials, or speakers/instructors without prior notice.

Refund Processing:
Refunds are processed within 7 business days from the receipt of the refund request. Eventura World is not liable for any penalties or expenses incurred due to an event's cancellation.

For additional information or clarification regarding our refund or cancellation policies, please contact our support team by phone or email us at support@eventura.us. Include your transaction ID, event ID, and event date in the subject of your email.